Clinical Trial Update: Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating initiation of LCZ696 (sacubitril/valsartan) therapy before vs after hospital discharge in patients with heart failure with reduced ejec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 4 | Status: COMPLETED | Results posted: 2021-04-26